Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

Journal of Biological Chemistry

Volumn 290, Issue 18, 2015, Pages 11649-11662

  Romagnuolo, Rocco ^a   Scipione, Corey A ^a   Boffa, Michael B ^a   Marcovina, Santica M ^b   Seidah, Nabil G ^c   Koschinsky, Marlys L ^a  

^a UNIVERSITY OF WINDSOR   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; METABOLISM;

HEPATOMA CELLS; LOW DENSITY LIPOPROTEIN RECEPTORS; PLASMA LIPOPROTEINS; SUBTILISIN;

LIPOPROTEINS;

APOLIPOPROTEIN A; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; BLOOD; HEK293 CELL LINE; HEPG2 CELL LINE; METABOLISM; PROTEIN TRANSPORT;

APOLIPOPROTEINS A; HEK293 CELLS; HEP G2 CELLS; HUMANS; LIPOPROTEIN(A); PROPROTEIN CONVERTASES; PROTEIN TRANSPORT; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84929493809     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.611988     Document Type: Article

References (65)

1. Boffa, M. B., and Koschinsky, M. L (2013) Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr. Atheroscler. Rep. 15, 360-366
2. Tsimikas, S., and Hall, J. L. (2012) Lipoprotein(a) as a potential causal genetic risk factor of CVD: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J. Am. Coll. Cardiol. 60, 716-721
3. McLean, J. W., Tomlinson, J. E., Kuang, W. J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., and Lawn, R. M. (1987) cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132-137
4. Gabel, B. R., and Koschinsky, M. I. (1995) Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry 34, 15777-15784
5. Koschinsky, M. L., Côté, G. P., Gabel, B., and van der Hoek, Y. Y. (1993) Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J. Biol. Chem. 268, 19819-19825
6. Becker, L., Cook, P. M., Wright, T. G., and Koschinsky, M.L. (2004) Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly. J. Biol. Chem. 279, 2679-2688
7. Hancock, M. A., Boffa, M. B., Marcovina, S. M., Nesheim, M. E., and Koschinsky, M. L. (2003) Inhibition of plasminogen activation by lipopro-tein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol. Chem. 278, 23260-23269
8. Marcovina, S. M., Albers, J. J., Wijsman, E., Zhang, Z., Chapman, N. H., and Kennedy, H. (1996) Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J. Lipid Res. 37, 2569-2585
9. Rader, D. J., Cain, W., Ikewaki, K., Talley, G., Zech, L. A., Usher, D., and Brewer, H. B., Jr. (1994) The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J. Clin. Invest. 93, 2758-2763
10. White, A. L., Guerra, B., and Lanford, R. E. (1997) Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J. Biol. Chem. 272, 5048-5055
11. Boerwinkle, E., Leffert, C. C., Lin, J., Lackner, C., Chiesa, G., and Hobbs, H. H. (1992) Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90, 52-60
12. Tam, S. P., Zhang, X., and Koschinsky, M. L. (1996) Interaction of a re-combinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2. J. Lipid Res. 37, 518-533
13. Floren, C. H., Albers, J. J., and Bierman, E. L. (1981) Uptake of Lp[a] lipoprotein by cultured fibroblasts. Biochem. Biophys. Res. Commun. 102, 636-639
14. Havekes, L., Vermeer, B. J., Brugman, T., and Emeis, J. (1981) Binding of Lp[a] to the low density lipoprotein receptor of human fibroblasts. FEBS Lett. 132, 169-173
15. Krempler, F., Kostner, G. M., Roscher, A., Haslauer, F., Bolzano, K., and Sandhofer, F. (1983) Studies on the role of specific cell surface receptors in the removal of lipoprotein[a] in man. J. Clin. Invest. 71, 1431-1441
16. Argraves, K. M., Kozarsky, K. F., Fallon, J. T., Harpel, P. C, and Strickland, D. K. (1997) The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J. Clin. Invest. 100, 2170-2181
17. März, W., Beckmann, A., Scharnagl, H., Siekmeier, R., Mondorf, U., Held, I., Schneider, W., Preissner, K. T., Curtiss, L. K., and Gross, W. (1993) Heterogeneous lipoprotein[a] isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/a 2-macroglobulin receptor. FEBS Lett. 325, 271-275
18. Niemeier, A., Willnow, T., Dieplinger, H, Jacobsen, C., Meyer, N., Hilpert, J., and Beisiegel, U. (1999) Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler. Thromb. Vasc. Biol. 19, 552-561
19. Yang, X. P., Amar, M. J., Vaisman, B., Bocharov, A. V., Vishnyakova, T.G., Freeman, L. A., Kurlander, R. J., Patterson, A. P., Becker, L. C., and Rema-ley, A. T. (2013) Scavenger receptor-BI is a receptor for lipoprotein(a). J. Lipid Res. 54, 2450-2457
20. Hofmann, S. L., Eaton, D. L., Brown, M. S., McConathy, W. J., Goldstein, J. L., and Hammer, R. E. (1990) Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J. Clin. Invest. 85, 1542-1547
21. Alonso, R., Andres, E., Mata, N., Fuentes-Jiménez, F., Badimón, L., López-Miranda, J., Padró, T., Muñiz, O., Díaz-Díaz, J. L., Mauri, M., Ordovás, J. M., and Mata, P., and SAFEHEART Investigators (2014) Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J. Am. Coll. Cardiol. 63, 1982-1989
22. Kraft, H. G., Lingenhel, A., Raal, F. J., Hohenegger, M., and Utermann, G. (2000) Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20, 522-528
23. Cain, W. J., Millar, J. S., Himebauch, A. S., Tietge, U. J., Maugeais, C., Usher, D., and Rader, D. J. (2005) Lipoprotein[a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein[a]. J. Lipid Res. 46, 2681-2691
24. Rader, D. J., Mann, W. A., Cain, W., Kraft, H. G., Usher, D., Zech, L. A., Hoeg, J. M., Davignon, J., Lupien, P., and Grossman, M. (1995) The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J. Clin. Invest. 95, 1403-1408
25. McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C, Ferrand, A. C, and Stein, E. A. (2012) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344-2353
26. Roth, E. M., McKenney, J. M., Hanotin, C, Asset, G., and Stein, E. A. (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367, 1891-1900
27. Desai, N. R., Kohli, P., Giugliano, R. P., ODonoghue, M. L., Somaratne, R., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., Scott, R., and Sabatine, M. S. (2013) AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipo-protein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 128, 962-969
28. Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H, Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., Huang, F., Xue, A., Albizem, M., Scott, R., and Stein, E. A. (2014) Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1, 300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63, 1278-1288
29. Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., Yang, J., Liu, T., Albizem, M., Scott, R., Sabatine, M. S., and PROFICIO Investigators (2014) Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur. Heart J. 35, 2249-2259
30. Gaudet, D., Kereiakes, D. J., McKenney, J. M., Roth, E. M., Hanotin, C., Gipe, D., Du, Y., Ferrand, A. C., Ginsberg, H. N., and Stein, E. A. (2014) Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am. J. Cardiol. 114, 711-715
31. Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) MutationsinPCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156
32. Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., and Chretien, M. (2003) The secretory pro-protein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 928-933
33. Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M. C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., Boileau, C., Brissette, L., Chrétien, M., Prat, A., and Seidah, N. G. (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865-48875
34. Abifadel, M., Rabès, J. P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., and Boileau, C. (2009) Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30, 520-529
35. Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nas-soury, N., Mayer, H., Nimpf, J., Prat, A., and Seidah, N. G. (2008) The proprotein convertase PCSK9 induces the degradation of low density li-poprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283, 2363-2372
36. Canuel, M., Sun, X., Asselin, M. C., Paramithiotis, E., Prat, A., and Seidah, N. G. (2013) Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One 8, e64145
37. Rohlmann, A., Gotthardt, M., Hammer, R.E., and Herz, J.(1998) Inducible inactivation ofhepatic LRP genebycre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101, 689-695
38. Frykman, P. K., Brown, M. S., Yamamoto, T., Goldstein, J. L., and Herz, J. (1995) Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipo-protein receptor. Proc. Natl. Acad. Sci. U.S.A. 92, 8453-8457
39. Marcovina, S. M., Albers, J. J., Gabel, B., Koschinsky, M. L., and Gaur, V. P. (1995) Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin. Chem. 41, 246-255
40. Romagnuolo, R., Marcovina, S. M., Boffa, M. B., Koschinsky, M. L. (2014) Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J. Lipid Res. 55, 625-634
41. Poirier, S., Mayer, G., Poupon, V., McPherson, P. S., Desjardins, R., Ly, K., Asselin, M. C., Day, R., Duclos, F. J., Witmer, M., Parker, R., Prat, A., and Seidah, N. G. (2009) Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J. Biol. Chem. 284, 28856-28864
42. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) Binding of proprotein conver-tase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612
43. Kwon, H. J., Lagace, T. A., McNutt, M. C., Horton, J. D., and Deisenhofer, J. (2008) Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. U.S.A. 105, 1820-1825
44. Miles, L. A., Fless, G. M., Scanu, A. M., Baynham, P., Sebald, M. T., Skocir, P., Curtiss, L. K., Levin, E. G., Hoover-Plow, J. L., and Plow, E. F. (1995) Interaction of Lp(a) with plasminogen binding sites on cells. Thromb. Haemost. 73, 458-465
45. Kosenko, T., Golder, M., Leblond, G., Weng, W., and Lagace, T. A. (2013) Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J. Biol. Chem. 288, 8279-8288
46. Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., and Seidah, N. G. (2007) The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8, 718-732
47. Wang, Y., Huang, Y., Hobbs, H. H., and Cohen, J. C. (2012) Molecular characterization of proprotein convertase subtilisin/kexin type 9-medi-ated degradation of the LDLR. J. Lipid Res. 53, 1932-1943
48. Ernst, A., Helmhold, M., Brunner, C., Pethö-Schramm, A., Armstrong, V. W., and Müller, H. J. (1995) Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipo-protein(a). J. Biol. Chem. 270, 6227-6234
49. Theuerle, J. D. (2009) Analysis of Lipoprotein(a) Catabolism. M.S. thesis, Queen's University, Kingston, Canada
50. Garcia, C. K., Wilund, K., Arca, M., Zuliani, G., Fellin, R., Maioli, M., Calandra, S., Bertolini, S., Cossu, F., Grishin, N., Barnes, R., Cohen, J. C., and Hobbs, H. H. (2001) Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292, 1394-1398
51. He, G., Gupta, S., Yi, M., Michaely, P., Hobbs, H. H., and Cohen, J. C. (2002) ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. J. Biol. Chem. 277, 44044-44049
52. Nguyen, A. T., Hirama, T., Chauhan, V., Mackenzie, R., and Milne, R. (2006) Binding characteristics of a panel of monoclonal antibodies against the ligand binding domain of the human LDLr. J. Lipid Res. 47, 1399-1405
53. Becker, L., Webb, B. A., Chitayat, S., Nesheim, M. E., and Koschinsky, M. L. (2003) A ligand-induced conformational change in apolipopro-tein(a) enhances covalent Lp(a) formation. J. Biol. Chem. 278, 14074-14081
54. Barrett, A. J., Kembhavi, A. A., Brown, M. A., Kirschke, H., Knight, C. G., Tamai, M., and Hanada, K. (1982) L-trans-Epoxysuccinyl-leucylamide(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine pro-teinases including cathepsins B, H and L. Biochem. J. 201, 189-198
55. Fenteany, G., and Schreiber, S.L.(1998) Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 273, 8545-8548
56. Dröse, S., Bindseil, K. U., Bowman, E. J., Siebers, A., Zeeck, A., and Alten-dorf, K. (1993) Inhibitory effect of modified bafilomycins and concanamy-cins on P-and V-type adenosinetriphosphatases. Biochemistry 32, 3902-3906
57. Tziomalos, K., Athyros, V. G., Wierzbicki, A. S., and Mikhailidis, D. P. (2009) Lipoproteina: where arewenow?Curr. Opin. Cardiol.24, 351-357
58. Gonbert, S., Malinsky, S., Sposito, A. C., Laouenan, H., Doucet, C., Chapman, M. J., and Thillet, J. (2002) Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 164, 305-311
59. van Wissen, S., Smilde, T. J., Trip, M. D., de Boo, T., Kastelein, J. J., and Stalenhoef, A. F. (2003) Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart 89, 893-896
60. Bea, A. M., Mateo-Gallego, R., Jarauta, E., Villa-Pobo, R., Calmarza, P., Lamiquiz-Moneo, I., Cenarro, A., Civeira, F. (2014) [Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia.] Clin. Inves-tig. Arterioscler. 26, 176-183
61. Soutar, A. K., McCarthy, S. N., Seed, M., and Knight, B. L. (1991) Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the Pro664 3 Leu mutation in the LDL receptor gene. J. Clin. Invest. 88, 483-492
62. Ghiselli, G., Gaddi, A., Barozzi, G., Ciarrocchi, A., and Descovich, G. (1992) Plasma lipoprotein(a) concentration in familial hypercholesterolemic patients without coronary artery disease. Metabolism 41, 833-838
63. Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116, 2995-3005
64. Strøm, T. B., Holla, Ø. L., Tveten, K., Cameron, J., Berge, K. E., and Leren, T. P. (2010) Disrupted recycling of the low density lipoprotein receptor by PCSK9 isnot mediated byresidues of the cytoplasmic domain. Mol. Genet. Metab. 101, 76-80
65. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N. G., Bernier, L., and Prat, A. (2004) Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454-1459